![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SOCS3 |
Gene summary for SOCS3 |
![]() |
Gene information | Species | Human | Gene symbol | SOCS3 | Gene ID | 9021 |
Gene name | suppressor of cytokine signaling 3 | |
Gene Alias | ATOD4 | |
Cytomap | 17q25.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O14543 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9021 | SOCS3 | AEH-subject3 | Human | Endometrium | AEH | 1.08e-08 | -4.67e-01 | -0.2576 |
9021 | SOCS3 | AEH-subject5 | Human | Endometrium | AEH | 4.06e-20 | -5.82e-01 | -0.2953 |
9021 | SOCS3 | EEC-subject1 | Human | Endometrium | EEC | 1.20e-11 | -4.69e-01 | -0.2682 |
9021 | SOCS3 | EEC-subject2 | Human | Endometrium | EEC | 1.61e-05 | -3.53e-01 | -0.2607 |
9021 | SOCS3 | EEC-subject3 | Human | Endometrium | EEC | 8.19e-11 | -2.36e-01 | -0.2525 |
9021 | SOCS3 | EEC-subject4 | Human | Endometrium | EEC | 4.03e-02 | -2.79e-01 | -0.2571 |
9021 | SOCS3 | EEC-subject5 | Human | Endometrium | EEC | 3.66e-16 | -5.33e-01 | -0.249 |
9021 | SOCS3 | GSM5276934 | Human | Endometrium | EEC | 3.49e-05 | -3.76e-01 | -0.0913 |
9021 | SOCS3 | GSM5276935 | Human | Endometrium | EEC | 1.70e-16 | -5.70e-01 | -0.123 |
9021 | SOCS3 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.35e-09 | -3.70e-01 | -0.1869 |
9021 | SOCS3 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 4.22e-15 | -5.28e-01 | -0.1875 |
9021 | SOCS3 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.82e-14 | -4.89e-01 | -0.1883 |
9021 | SOCS3 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.50e-12 | -3.78e-01 | -0.1934 |
9021 | SOCS3 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 5.63e-15 | -2.74e-01 | -0.1917 |
9021 | SOCS3 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.96e-16 | -2.31e-01 | -0.1916 |
9021 | SOCS3 | LZE4T | Human | Esophagus | ESCC | 1.94e-05 | -4.36e-01 | 0.0811 |
9021 | SOCS3 | LZE7T | Human | Esophagus | ESCC | 1.83e-02 | -8.49e-02 | 0.0667 |
9021 | SOCS3 | LZE24T | Human | Esophagus | ESCC | 7.21e-23 | 2.27e+00 | 0.0596 |
9021 | SOCS3 | LZE21T | Human | Esophagus | ESCC | 2.17e-04 | 1.53e+00 | 0.0655 |
9021 | SOCS3 | LZE6T | Human | Esophagus | ESCC | 2.87e-04 | -3.98e-01 | 0.0845 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00607117 | Prostate | BPH | labyrinthine layer development | 17/3107 | 44/18723 | 3.88e-04 | 2.84e-03 | 17 |
GO:00082867 | Prostate | BPH | insulin receptor signaling pathway | 33/3107 | 116/18723 | 9.41e-04 | 5.94e-03 | 33 |
GO:19908236 | Prostate | BPH | response to leukemia inhibitory factor | 27/3107 | 95/18723 | 2.65e-03 | 1.41e-02 | 27 |
GO:19908306 | Prostate | BPH | cellular response to leukemia inhibitory factor | 26/3107 | 94/18723 | 4.70e-03 | 2.25e-02 | 26 |
GO:00606742 | Prostate | BPH | placenta blood vessel development | 11/3107 | 30/18723 | 6.48e-03 | 2.92e-02 | 11 |
GO:006145816 | Prostate | Tumor | reproductive system development | 133/3246 | 427/18723 | 1.24e-12 | 1.15e-10 | 133 |
GO:004860815 | Prostate | Tumor | reproductive structure development | 131/3246 | 424/18723 | 3.48e-12 | 2.89e-10 | 131 |
GO:004232618 | Prostate | Tumor | negative regulation of phosphorylation | 112/3246 | 385/18723 | 6.17e-09 | 2.42e-07 | 112 |
GO:004593619 | Prostate | Tumor | negative regulation of phosphate metabolic process | 124/3246 | 441/18723 | 9.08e-09 | 3.44e-07 | 124 |
GO:001056319 | Prostate | Tumor | negative regulation of phosphorus metabolic process | 124/3246 | 442/18723 | 1.05e-08 | 3.88e-07 | 124 |
GO:000170115 | Prostate | Tumor | in utero embryonic development | 106/3246 | 367/18723 | 2.37e-08 | 8.09e-07 | 106 |
GO:190165315 | Prostate | Tumor | cellular response to peptide | 104/3246 | 359/18723 | 2.71e-08 | 8.90e-07 | 104 |
GO:000189016 | Prostate | Tumor | placenta development | 52/3246 | 144/18723 | 4.96e-08 | 1.52e-06 | 52 |
GO:004343418 | Prostate | Tumor | response to peptide hormone | 113/3246 | 414/18723 | 2.24e-07 | 5.42e-06 | 113 |
GO:000193318 | Prostate | Tumor | negative regulation of protein phosphorylation | 97/3246 | 342/18723 | 2.36e-07 | 5.60e-06 | 97 |
GO:000189215 | Prostate | Tumor | embryonic placenta development | 34/3246 | 82/18723 | 2.41e-07 | 5.65e-06 | 34 |
GO:000176314 | Prostate | Tumor | morphogenesis of a branching structure | 62/3246 | 196/18723 | 6.78e-07 | 1.39e-05 | 62 |
GO:007137514 | Prostate | Tumor | cellular response to peptide hormone stimulus | 83/3246 | 290/18723 | 1.14e-06 | 2.16e-05 | 83 |
GO:003286915 | Prostate | Tumor | cellular response to insulin stimulus | 63/3246 | 203/18723 | 1.15e-06 | 2.18e-05 | 63 |
GO:006113813 | Prostate | Tumor | morphogenesis of a branching epithelium | 57/3246 | 182/18723 | 2.66e-06 | 4.45e-05 | 57 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0493220 | Endometrium | AEH | Non-alcoholic fatty liver disease | 67/1197 | 155/8465 | 5.91e-19 | 1.75e-17 | 1.28e-17 | 67 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa04932110 | Endometrium | AEH | Non-alcoholic fatty liver disease | 67/1197 | 155/8465 | 5.91e-19 | 1.75e-17 | 1.28e-17 | 67 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0493225 | Endometrium | EEC | Non-alcoholic fatty liver disease | 67/1237 | 155/8465 | 3.53e-18 | 1.06e-16 | 7.87e-17 | 67 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa046687 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0493235 | Endometrium | EEC | Non-alcoholic fatty liver disease | 67/1237 | 155/8465 | 3.53e-18 | 1.06e-16 | 7.87e-17 | 67 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0466814 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa051609 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SOCS3 | SNV | Missense_Mutation | rs866275313 | c.385N>T | p.Pro129Ser | p.P129S | O14543 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SOCS3 | SNV | Missense_Mutation | novel | c.22N>A | p.Pro8Thr | p.P8T | O14543 | protein_coding | tolerated(0.17) | benign(0.045) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
SOCS3 | deletion | Frame_Shift_Del | novel | c.347_354delNNNNNNNN | p.Arg116LeufsTer24 | p.R116Lfs*24 | O14543 | protein_coding | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
SOCS3 | insertion | Frame_Shift_Ins | novel | c.299dupG | p.Ser101GlnfsTer42 | p.S101Qfs*42 | O14543 | protein_coding | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
SOCS3 | SNV | Missense_Mutation | c.160N>A | p.Gly54Ser | p.G54S | O14543 | protein_coding | tolerated(0.44) | benign(0.055) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SOCS3 | SNV | Missense_Mutation | c.281N>A | p.Arg94His | p.R94H | O14543 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
SOCS3 | SNV | Missense_Mutation | c.82A>C | p.Lys28Gln | p.K28Q | O14543 | protein_coding | tolerated(0.15) | benign(0.312) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SOCS3 | SNV | Missense_Mutation | rs780147259 | c.589N>A | p.Val197Ile | p.V197I | O14543 | protein_coding | tolerated(0.2) | possibly_damaging(0.739) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SOCS3 | deletion | Frame_Shift_Del | c.299delG | p.Gly100AlafsTer79 | p.G100Afs*79 | O14543 | protein_coding | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
SOCS3 | deletion | Frame_Shift_Del | c.299delN | p.Gly100AlafsTer79 | p.G100Afs*79 | O14543 | protein_coding | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9021 | SOCS3 | KINASE, CLINICALLY ACTIONABLE | ANTISENSE OLIGONUCLEOTIDES | 15939448 |
Page: 1 |